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Introduction: 
Since its description some 100 years ago by Skene, vulvar vestibulitis has been an elusive 
disorder with poorly understood etiology, pathophysiology, and treatment 1. After an 80 
year hiatus in the literature, in 1987 Friedrich proposed the first clinical diagnostic 
criteria for vulvar vestibulitis: 1) Severe pain on vestibular touch and entry dyspareunia, 
2) tenderness to pressure localized within the vestibule, and 3) physical findings limited 
to erythema of various degrees 2• 3. The pain may be present only during attempted coitus, 
or may be troublesome during other daily activities. The population prevalence of vulvar 
vestibulitis is unknown. In a private practice setting, Goetsch reported 15% of210 
consecutively evaluated patients over 6 months met criteria for vestibulitis 4 
Despite the reported high prevalence of this disorder, randomized trials evaluating 
medical treatments for vulvar vestibulitis (VVS) are limited to two negative studies 25 . 
Nyirjesy eta! reported similar response to topical Cromolyn cream (38%) vs. placebo 
(46%) over 3 months of therapy. Similarly, long term treatment with fluconazole, low 
oxalate diet and calcium produced improvement equivalent to low oxalate diet alone 5• 
In 30 women treated with a series of interferon alpha-2b injections, 17 of whom had 
human papilloma virus (HPV) proven on biopsy, Horowitz reported clinically significant 
improvement in 88%. These results were not replicated by other investigators totaling 89 
study participants 2' 6' 9• 
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Several investigators have compared cognitive behavioral therapy and surgery with 
conflicting results. In a randomize trail involving I 4 women Schultz at el showed no 
additional benefit of surgery above cognitive behavioral therapy alone10. In another 
randomized trial, Bergeron et a! found that vestibuloplasty, cognitive-behavioral therapy, 
and surface electromyographic biofeedback all produced improvement at 6 months 
follow up, with vestibuloplasty producing the best result. He, however, cautioned against 
the apparent superiority of vestibuloplasty since 7 women assigned to this arm did not L 
proceed with the treatment 11 . Bomstein et a! conducted a randomized trial assessing the 
optimal surgical approach. He concluded that complete resection of the tissue 
(perineoplasty) results in full resolution of the symptoms (9/1 1 women) while vestibular 
undercutting failed to result in any improvement (10 women)12. 
In uncontrolled clinical series, the surgical approach to treatment of vulvar vestibulitis 
seems to have the highest reported success rate. For example, McCormack reported 80% 
5-year success rate, while the review of literature by Masheb et a! showed a 60-89% 
improvement at 6 months; 10% were worse with surgery 13• 14. In contrast, laser treatment 
for VVS as an alternative to vestibuloplasty has had disappointing results; in most cases it 
results in worsening symptoms and poor healing 13 • 
Over the past five years, on the basis of clinical and histopathologic data vulvar 
. 
vestibulitis has became conceptualized as a neuroinflammtory condition. 15-18. Vulvar L 
vestibulitis (VVS) clinically resembles post-herpetic neuralgia (PHN) in that affected 
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women demonstrate anodynia to touch, and respond variably to treatment, perhaps based 
on the severity of the nerve injury 19. A greater than expected proportion of women with 
VVS also suffer from interstitial cystitis, a disorder widely held to be neuro inflammatory 
in nature 20' 21 • 
Boham-Starke's works suggests that in the case ofVVS, initial nerve injury provokes 
sensitization of nociceptors and release of neuropeptides that maintain an inflammatory 
process 16• 18. In case ofPHN, subgroup with mechanical anodynia responds to prolong 
topical treatment with local anesthetics, Lidoderm patch®22• 
Vulvar vestibulitis is clinicany similar to PHN in that it appears to have variable degrees 
of severity. Similar to PHN, majority of women with VVS have touch-invoked anodynia. 
As such, one might see a similar reduction in pain ofVVS using established treatments 
for PHN with touch invoked anodynia. The objective of this study was to assess the 
response of women with VVS to treatment with prolong local anesthetics, 5% lidocaine 
ointment. 
Material and Methods: 
Between Nov. 1999 and March of2001, an women referred to the University of North 
Carolina (UN C) Pelvic Pain Clinic for management of vulvar pain were evaluated for 
eligibility for enrollment. This study (case series) was approved by the Institutional 
Review Board. An patients referred for evaluation of vulvar pain underwent a standard 
history and physical examination. After completion of the history, they were asked to rate 
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their discomfort level on daily activity and intercourse using a Visual Analog Scale 
(VAS). 
We performed comprehensive physical examinations on all women. We used cotton 
tipped applicator to touch labia major, labia minor and the vestibule, and we recorded 
presence or absence of allodynia (perception of pinprick when touched with the 
applicator), sensory loss, and any visible inflammatory changes. 
A diagnosis ofvulvarvestibulitis was made (or confirmed) using Friedrich's criteria: 
presence of exquisite tenderness at the vestibule, vestibular fourchette, and vestibulo-
hymenal junction with or without corresponding visual changes of erythema in the 
absence of known pathology. A diagnosis ofvulvodynia was made based on presence of 
daily-generalized pain/discomfort over vulva in the absence of any dermatologic or 
recognizable pathologic processes. 
Women with dermatologic conditions (lichen sclerosis, lichen planus), chronic recurrent 
infectious disorders (e.g. chronic candida infections), vulvar intraepithelial neoplasia 
(VIN), and atrophic and ectopic dermatitis were excluded from the study unless they had 
concomitant VVB or vulvodynia. Women with a diagnosis of vulvar vestibulitis and 
generalized vulvodynia were offered the treatment. Additionally, women with clinically 
suspected diagnosis of vulvar vestibulitis, and generalized vulvodynia with other 
concomitant diagnosis (such as interstitial cystitis, vaginismus, deep dyspareunia 
associated with endometriosis, proctalgia fugax) were also offered the treatment. All 
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women with diagnosis of vulvar vestibulitis, vulvodynia, and mixed diagnosis were ~--
offered enrollment in the study. 
After the diagnosis was made, study participants were instructed in the treatment 
procedure. Using a mirror, the anatomy of the involved area was reviewed with the 
patient. Patients were instructed to apply at bedtime a copious amount of 5% Xylocaine® 
ointment to the affected area at vestibulo-hymenaljunction. Next, they were asked to 
place cotton ball soaked in 5% Xylocaine in the vestibule to assure constant application. 
Patients were instructed to use the treatment nightly, for 8 hours each night. They were 
also instructed to refrain from intercourse for the first 4 weeks of the treatment. A week 
prior to their follow-up appointment, they were instructed to resume sexual activity. 
During the initial phase of the study it became clear that most patients responded within 
6-8 weeks of starting the therapy; hence, resumption of sexual activity was commonly 
delayed until at least 6 weeks of nightly therapy. 
A repeat VAS score was obtained for daily activity and intercourse related discomfort in 
the follow up visit. Patients were also asked about the ability to have intercourse in both 
initial and follow up visits. Patients were reported as being able to have intercourse if 
they were able to tolerate intercourse during a given month, regardless of frequency or 
degree of discomfort. Those who were functionally celibate due to severity of symptoms 
were reported as not being able to have intercourse. Regardless of the patients' 
compliance with treatment or subsequent additional diagnoses the data for all the patients 
who were offered treatment was analyzed. 
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A combination of chart review, telephone interview and direct interview was used to 
obtain additional demographics on the patients. Long-term response to treatment was 
assessed by sending a follow up questionnaire and VAS rating a minimum of 6 months 
after the initiation of treatment. 
The primary outcome was a change in overall and intercourse related VAS with 
treatment. We also assessed patients for a 'clinic'illy significant reduction in pain' by 
looking at their ability to have intercourse, and a 50% reduction in intercourse related 
pain post treatment. 
Statistical analysis was performed using STAT A software (college station, TX). 
Univariant descriptive tabulations were followed by bivariante analysis. Paired t -tests 
were used to assess changes in continuous outcomes; Pearson's x2 and Fisher exact tests 
were used for categorical data. 
Results: 
A total of 7 4 patients were offered the treatment. Of the 7 4 patients, 2 patient declined 
treatment, 1 patient was spontaneously pain free within in a week of the visit and did not 
use the treatment, 7 patients did not show up after the first visit with no available follow 
up/demographic data. The reported data is based on the remaining cohort of 64 patients. 
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Demographic data is shown in table I. Patients' mean age was 30±6 years, and 95% of 
patients had seen at least one physician with an average of 3±2 physicians in 32 months 
(5-216) prior to their visit to our clinics. The primary diagnosis was vestibulitis in 47 
women (73%) and vulvodynia in 4 (7%) women; 13 (20%) women had the other 
concomitant diagnosis (vaginismus, 4; culture proven chronic recurrent yeast infection, 3; 
recurrent herpes,!; lichen sclerosis, 1; proctalgia fugax, I; obsessive compulsive disorder 
involving genital cleansing, 1; post episiotomy perineoplasty pain, 2). The majority of the 
women were nulliparous. Forty-nine percent reported having had only one partner. 
Thirteen percent of women had a known diagnosis of endometriosis, but endometriosis 
was not the primary cause of dyspareunia in the majority. The majority of women had 
various other treatments as reported in table 2. Women who had a trial oflidocaine 
(before our evaluation) had used it prior to intercourse and on as needed basis. 
There was no association between prior use oflidocaine and response to the treatment 
regimen. On average, it took 7±3 weeks of nightly therapy to see any significant 
improvement. A significantly higher proportion of women using the treatment reported 
ability to have intercourse post-treatment compared to pre-treatruent, 73% vs. 40% 
(P=O.OOI). Overall, the pain rating post-treatment was 12.40 (5.20,19.58) points lower 
that pre-treatment pain ratings, p=O.OOl. Intercourse related pain score was 39.53 (30.84, 
48.27) points lower post treatment, p<O.OOOOI (table 3). 
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Clinically meaningful response to treatment was defined as a 50% or more declines in 
pain score with treatment. Neither the number of months with symptoms, presence of 
endometriosis or symptom onset associated with childbirth was related to response to 
treatment. Women with intersitial cystitis were 6.31 (1.18,32.90) less likely to respond to 
treatment than those without IC. Women with vulvar surgery also tended to be less likely 
to respond to treatment but the difference did not reach statistical significance. There was 
no statistically significant difference in improvement based on route of delivery or 
number of sexual partners. Women with other vulvar diseases were less likely than ~-
women with VS and VD to respond to treatment (p=0.009). 
Forty-seven percent (30/64) of women responded to the 6 month follow up questionnaire. I 
' 
Women who responded to the questionnaire were 1.58(1.09-2.28) times more likely to 
have reported a 50% improvement on their initial treatment. On average, respondents 
were in treatment for 8± 5 months. Seventy percent of those responding to the follow-up 
assessment reported on-going use of 5% Xylocaine® ointment. Within this subset, 17% 
(N=S) reported nightly applications, 23% (N=7) reported application several times a 
week, and 27% (N =8) reported using the treatment several times a month. The mean 
VAS on 6 month follow up was 21±23, down 13 points from pre-treatment daily 
discomfort, P=0.03. Intercourse related VAS score was 31±26, down 31 points from the 
pretreatment value, P<O.OOOO!. 
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Discussion 
Most patients with post-herpetic neuralgia describe one of three types of pain: 1) 
spontaneous, constant burning, throbbing, aching pain; 2) intermittent sharp, stabbing, 
shooting, lancinating pain, which may also be spontaneous; and 3) dysesthetic pain 
provided by light tactile stimulation (allodynia), which usually lasts well beyond the 
duration of the stimulus (hyperpathia). When patients with post-herpetic neuralgia are 
carefully examined, the involved skin almost always shows pigment changes, scarring, 
and variety of sensory abnormalities (Wallace, 1997). The majority of the patients with 
VVS similarly complain of dysesthetic pain with few complaining of constant burning 
pam. i 
F 
Studies of subgroups with distinct pain characteristics show different patterns of nerve 
injury, making post-herpetic neuralgia patients a heterogeneous population with different 
responses to various treatments. The three subtypes are: 1) an "irritable nociceptor" group 
with minimal deafferentation and touch-invoked allodynia due to peripheral nociceptor 
input, 2) a deafferentation group with both marked sensory loss and no allodynia, and 3) 
a deafferentation group with both sensory loss and allodynia due to central reorganization 
(Rowbotham, 1998). VVS patients appear to fall primarily into the "irritable nociceptor" 
group. 
Bohm-Starke conducted the first study characterizing the sensory abnormalities in 
women with vestibulitis. He documented evidence of nociceptor sensitization signified 
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by diminished threshold for punctate mechanical stimulation, cold, heat, and vibratory 
stimuli over the posterior vestibule. Furthermore, in some women she noted evidence of 
somatosensory abnormalities over the anterior vestibular mucosa. Coupled with 
morphological studies showing proliferation of c-fibers and presence of calcitonin gene-
related peptide, documented somatosensory dysfunction in VVS suggest a neuropathic 
process similar to what is documented in PHN. Bohm-Starke suggested that any 
treatment should be directed at destroying superficial nociceptor nerve endings (i.e. 
)_ 
surgery) or reduction of neuronal hyperexcitability by ion channel blockers (something 
we choose to investigate, lidocaine). Lidocaine is a sodium channel blocker that prevents 
nerve conduction of sensory impulses. The small uumyelinated nerve fibers (C-fibers) 
which conduct pain, temperature, and autonomic activity are most sensitive to action of 
local anesthetics (Harvey, 1992). Lidocaine has a slow onset of action with moderate 
duration which makes it an ideal compound for chronic pain disorder such as post-
herpetic neuralgia and vestibulitis. Continuous exposure to lidocaine inhibits "irritable 
nociceptors" and is the purported mechanism by which it provides benefit in treatment of 
chronic pain. 
PHN patients with touch-evoked allodynia, and relatively preserved sensation often 
obtain marked relief from topical application of local anesthetic (Fields, 1998). Topical 
and injected local anesthetics have been found effective in both controlled and 
uncontrolled studies23' 24 . Some patients using topical anesthetics attain sustained 
quiescence, whereas others many need to use treatment for many years to maintain pain 
relief (Galer, 1999). In this group with severe symptoms, lidocaine has been the only 
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treatment that significantly relieves their pain. In such patients, tolerance to lidocaine 
patch therapy does not occur nor do adverse events with several years of chronic daily 
application (Galer, 1999). 
We patterned our regimen after the initial trial done by Rowbotham using 5% lidocaine 
under a dressing for a 12 hour period. Given the anatomic difficulty of covering the 
vestibular region, we began using a medication-coated cotton ball over the 8 hours of 
sleep. Our experience is that the cotton ball remains in place without any difficulty and is 
well tolerated. 
The documented success of biofeedback is also consistent with the hypothesis of 
nociceptor hypersensitivity. Damaged c-fibers, unlike intact neurons, are not affected by 
sympathetic outflow (Field, 1998). After a nerve injury surviving cutaneous afferents 
develop noradrenergic sensitivity (Chahal, 1992). Foster eta!, documented increased 
uretheral pressure profile in women with vestibulitis. He hypothesized that there is an 
additional functional component to the pain experienced with vestibulitis that is 
"sympathetically mediated." (Foster, 1993). 
In our clinical experience, patients with interstitial cystitis invariably tend to have 
involvement of anterior vestibule, characterized by exquisite allodynia. Furthermore, 2 of 
the 6 women with IC reported numbness (these two had severe IC for many years), or 
limited perception of touch on the labia minora. Patients with IC were significantly less 
likely to respond to our treatment regimen than those without IC. We noted clinically 
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women with severe allodynia over the anterior vestibule tended to not respond as well to ~-
the treatment. Those with prior surgery responded favorably to the treatment as long as 
the area of allodynia and tenderness was limited to the posterior vestibule. 
We recognize that this preliminary work is limited by several factors: the umnasked 
nature of the medication use, limited long term follow up, limited follow up response 
rate, and our patients' desire to provide a socially desirable responses. It is unlikely that 
the patient and physician related factors could fully explain the noted improvement in L 
women at the most sever end of the symptom spectrum. Most of these women have 
suffered for a long time. Thus it is unlikely that patients' desire to provide a socially 
desirable outcome have a major impact on our results. Inherent limitation of this study is 
voluntary reliance on patients' response. Those who responded to our 6 months follow up 
questionnaire were more likely to have had an improvement in their symptoms. 
Assuming absence of any long -term benefit in non-responder the efficacy of this 
treatment regimen will be limited. However, we feel that even a 50% percent response 
rate in the severely affected population of women presents a viable alternative to a 
definite surgical intervention. 
We are encouraged by the relatively rapid and sustained improvement among those who L 
experienced benefit. The observed responses in women who are at the most severe end of 
the symptom spectrum is among many reasons that a randomized trial must be conducted 
to further investigate the effectiveness of this treatment regimen 
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Table 1. Characteristics of patient population 
Women on treatment with overnight 5% Xylocaine 
Mean Years ±sd 30±6 yrs. (n-63) 
Race 
White 94% (n=63) 
Black 2% 
Others 2% 
Duration of (n-63) 
Symptoms (months)* 32 (5-216) 
Diagnosis (n-64) 
Vulvar vestibulitis (VS) 47(73%) 
Vu1vodynia (VD) 3(5%) 
VS+VD 1(2%) 
VS+others 13(20%) 
Nulliparous 73% (n-64) 
Symptom associated with child birth 14% (n-62) 
NSVD 10% 
CIS 4% 
Endometriosis 13% (n-60) 
Interstitial cystitis 10% (n-60) 
No history of STD 87% (n-60) 
Number of sexual partners (n-47) 
1 23(49%) 
2-5 18(38%) 
5< 6 (14%) 
Number of physician seen 3±2 (n-47) 
L 
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Table 2. Treatments used prior to overnight use of 5% Xylocaine® 
Used Lidocaine 23(39%) (n-59) 
Used Elavil® 24(44%) (n-55) 
Used topical estrogen cream 41(69%) (n-59) 
Used Herbal remedies 12(20%) (n-59) 
TCA application 10(17%) (n-58) 
Topical steroids 32(54%) (n-59) 
Metronidazole gel 26(45%) (n-58) 
Antifungal cream 35(59%) (n-59) 
Surgical procedure for treatment ' 6(10%) (n-63) 
*Values are given as median values and ranges 
'Laser ablation, revision of episiotomy, vestibuloplasty, etc 
Table 3. Result of treatment with 5% Xylocaine 
Before treatment After treatment 
Ability to have 40% 78% Pearson i = 11; P=O.OOl 
intercourse 
Before treatment After treatment Mean difference (95% CI) 
Overall VAS 28.77 16.38 12.40 (5.20,19.58)* 
score 
Intercourse 75.20 35.67 39.53 (30.84,48.27)' 
VAS score 
* - ' p 0.001 p<0.00001 
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